ProKidney

Update in progress

PROK (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ProKidney Corp. is a clinical-stage biotechnology company developing cell therapies for chronic kidney diseases in the United States. It is advancing rilparencel, an autologous renal cell therapy, in Phase III for advanced chronic kidney disease and type 2 diabetes. It also develops cryopreserved rilparencel assets: REGEN-006 and REGEN-008 (Phase III), REGEN-002, REGEN-003, REGEN-007 (Phase II), and REGEN-004 (Phase I). Founded 2015, based in Winston-Salem, NC.

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.42; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive